CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON
Ireland
20150087.3
Filed on 2014-12-16
20150087.3
Filed on 2014-12-16
CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON
United Kingdom
20150087.3
Filed on 2014-12-16
20150087.3
Filed on 2014-12-16
CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON
France
20150087.3
Filed on 2014-12-16
20150087.3
Filed on 2014-12-16
CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON
Spain
20150087.3
Filed on 2014-12-16
20150087.3
Filed on 2014-12-16
CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON
Germany
20150087.3
Filed on 2014-12-16
20150087.3
Filed on 2014-12-16
CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON
Switzerland
20150087.3
Filed on 2014-12-16
20150087.3
Filed on 2014-12-16
CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON
Belgium
20150087.3
Filed on 2014-12-16
20150087.3
Filed on 2014-12-16
TRITERPENE AMINE DERIVATIVES
Hong Kong
62021037592.4
Filed on 2021-08-26
62021037592.4
Filed on 2021-08-26
NEAR INFRARED PHOTOIMMUNOTHERAPY (NIR-PIT) COMBINATION THERAPY TO TREAT CANCER
Patent Cooperation Treaty
PCT/US2022/014448
Filed on 2022-01-28
PCT/US2022/014448
Filed on 2022-01-28
Chimeric Antigen Receptors Targeting B-cell Maturation Antigen
Japan
2021-196490
Filed on 2021-12-02
2021-196490
Filed on 2021-12-02